EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia

Brian A Bergmark iD, Nicholas A Marston, Thomas A Prohaska, Veronica J Alexander, Andre Zimerman, Filipe A Moura, Yu Mi Kang, Julia Weinland, Sabina A Murphy, Erica L Goodrich, Shuanglu Zhang, Dan Li und 7 weitere

New England Journal of Medicine · 02.10.2025 · 393 (13) · 1279-1291

DOI: 10.1056/nejmoa2507227 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.10.2025. Verfasst von Brian A Bergmark und 18 weiteren Autor:innen. Beteiligte Einrichtung: TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Hypertriglyceridemia, Oligonucleotides, Oligonucleotides, Antisense. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: NIDDK NIH HHS, Ionis Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein C-IIIHypertriglyceridemiaOligonucleotidesOligonucleotides, AntisenseTriglyceridesAgedFemaleHumansMaleMiddle AgedCardiovascular DiseasesDouble-Blind MethodInjections, SubcutaneousSeverity of Illness IndexTreatment Outcome

Substanzen

Apolipoprotein C-IIIOligonucleotidesOligonucleotides, AntisenseTriglyceridesAPOC3 protein, humanolezarsen

Autor:innen und Institutionen

  • TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston.
  • Harvard Medical School, Boston.
  • Ionis Pharmaceuticals, Carlsbad, CA.
  • MOVE Academic Research Organization, Hospital Moinhos de Vento, Moinhos de Vento College of Health Sciences, Porto Alegre, Brazil.
  • Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT.
  • VA Connecticut Healthcare System, West Haven, CT.

ORCID-Profile: Brian A Bergmark

Förderung

  • NIDDK NIH HHS
  • Ionis Pharmaceuticals

Zitieren

APA

Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Weinland, J., Murphy, S. A., Goodrich, E. L., Zhang, S., Li, D., Banach, M., Stroes, E., Lu, M. T., Tsimikas, S., Giugliano, R. P., Sabatine, M. S., & Essence–TIMI 73b Investigators (2025). Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. New England Journal of Medicine, 393(13), 1279-1291. https://doi.org/10.1056/nejmoa2507227

Vancouver

Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. New England Journal of Medicine. 2025;393(13):1279-1291. doi:10.1056/nejmoa2507227

BibTeX
@article{Bergmark2025,
  author = {Bergmark, Brian A and Marston, Nicholas A and Prohaska, Thomas A and Alexander, Veronica J and Zimerman, Andre and Moura, Filipe A and Kang, Yu Mi and Weinland, Julia and Murphy, Sabina A and Goodrich, Erica L and Zhang, Shuanglu and Li, Dan and Banach, Maciej and Stroes, Erik and Lu, Michael T and Tsimikas, Sotirios and Giugliano, Robert P and Sabatine, Marc S and Essence–TIMI 73b Investigators, Essence–TIMI 73b Investigators},
  title = {Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {13},
  pages = {1279--1291},
  doi = {10.1056/nejmoa2507227}
}
Kostenlos starten →